Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Orthogonal Acyl Acceptor Substrate Pairs and hQC Improve Sequential Ligation by Peptide Asparaginyl Ligases.
Journal: Bioconjugate chemistry
Published: May 22, 2026
HER2-targeted PET/CT in breast cancer: a systematic review of lesion-level concordance with pathology.
Journal: European journal of radiology
Published: April 13, 2026
HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
Journal: Frontiers in oncology
Published: February 17, 2026
Kinetic modelling of [⁶⁸Ga]Ga-FAPI-46 PET in pancreaticobiliary lesions: distinguishing cancer from pancreatitis.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 21, 2026
First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer.
Journal: EJNMMI research
Published: January 14, 2026
Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 18, 2025
Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 04, 2025
Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 03, 2025
A Call for Common Sense in the Use of Molecular Imaging.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 10, 2025
Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model.
Journal: Nuklearmedizin. Nuclear medicine
Published: March 18, 2025
Reply to Vaz et al., Editorial Commentary: Should "Heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?
Journal: European journal of nuclear medicine and molecular imaging
Published: January 02, 2025
Last Updated: 09/26/2026